IDP 126

Drug Profile

IDP 126

Alternative Names: IDP126

Latest Information Update: 12 Mar 2016

Price : $50

At a glance

  • Originator Valeant Pharmaceuticals International
  • Class Antiacnes
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Acne

Most Recent Events

  • 05 Jun 2017 Valeant Pharmaceuticals plans a phase II trial for Acne vulgaris(NCT03170388)
  • 13 Jan 2016 Clinical trials in Acne in USA before January 2016 (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top